Sugi Predict

Sugi Predict / Compounds / SCHEMBL1821346

SCHEMBL1821346

SCHEMBL1821346

CC(C)(C)OC(=O)N1CCC(n2cc(-c3cnc(N)c(OCCc4c(Cl)ccc(F)c4Cl)c3)cn2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K3 Q8IVH8 8/20 0.61
▸ JAK2 O60674 6/20 0.61
▸ MET P08581 12/20 0.52
▸ ALK Q9UM73 5/20 0.51
▸ JAK3 P52333 3/20 0.51
▸ PLK4 O00444 2/20 0.51
▸ AURKA O14965 2/20 0.51
▸ DCLK1 O15075 2/20 0.51
▸ PRKD3 O94806 2/20 0.51
▸ ABL1 P00519 2/20 0.51
▸ NTRK1 P04629 2/20 0.51
▸ INSR P06213 2/20 0.51
▸ LCK P06239 2/20 0.51
▸ FES P07332 2/20 0.51
▸ CSF1R P07333 2/20 0.51
▸ LYN P07948 2/20 0.51
▸ RET P07949 2/20 0.51
▸ IGF1R P08069 2/20 0.51
▸ ROS1 P08922 2/20 0.51
▸ SRC P12931 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28341040 0.90 MAP4K3 (0.64) MAP4K3JAK2METALKJAK3
SCHEMBL16245284 0.89 MET (0.51) MAP4K3JAK2METALKJAK3
SCHEMBL16245172 0.89 MET (0.49) MAP4K3JAK2METALKJAK3
SCHEMBL28426063 0.85 MAP4K3 (0.62) MAP4K3JAK2METALKJAK3
SCHEMBL14812410 0.85 JAK2 (0.65) MAP4K3JAK2METALKJAK3
SCHEMBL1582264 0.84 MAP4K3 (0.60) MAP4K3JAK2METALKJAK3
SCHEMBL1902039 0.84 MET (0.73) MAP4K3JAK2METALKJAK3
SCHEMBL30753163 0.84 MET (0.73) MAP4K3JAK2METALKJAK3
SCHEMBL16245273 0.84 MET (0.73) MAP4K3JAK2METALKJAK3
SCHEMBL1581558 0.84 MET (0.73) MAP4K3JAK2METALKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108341802-B Synthesis method of antineoplastic drug crizotinib 浙江科聚生物医药有限公司 2020-09-08 — — CN disclosed
US-20140350050-A1 PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE TELIGENE LTD (CN) 2014-11-27 — — US disclosed
EP-2758387-A1 PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE Teligene Ltd. (CN) 2014-07-30 — — EP disclosed
WO-2013041038-A1 PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE TELIGENE LTD. (CN) 2013-03-28 — — WO disclosed
EP-2315601-A1 COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER Pierre Fabre Médicament (FR) 2011-05-04 — — EP disclosed
WO-2010003992-A1 COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2010-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350050-A1 PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE MAP3K20, MAP3K1, MAP3K12 MAP4K3 19/4885JAK2 299/4885MET 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.